国际肿瘤学杂志

国际肿瘤学杂志 ›› 2012, Vol. 39 ›› Issue (8): 703-706.

• 综述 • 上一篇    下一篇

小肠癌化疗及分子靶向治疗

吴婧婧,顾康生   

  1. 230022 合肥，安徽医科大学第一附属医院肿瘤内科
  • 出版日期:2012-09-22 发布日期:2012-09-24
  • 通讯作者: 顾康生，E-mail：gks63@tom.com E-mail:gks63@tom.com

Chemotherapy and molecular targeted therapy for small intestine cancer

 WU  Jing-Jing, GU  Kang-Sheng   

  1. Department of Medical Oncology, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
  • Online:2012-09-22 Published:2012-09-24
  • Contact: GU Kang-sheng, E-mail: gks63@tom.com E-mail:gks63@tom.com

PDF

2265

被引次数

7

摘要： 小肠恶性肿瘤早期临床表现无特异性，总体预后较差，5年总生存率约30%，中位生存期约19个月。回顾性分析提示术后辅助化疗有可能改善无瘤生存期，但总生存期未见明显改善；对肿瘤分期相对较晚、有区域淋巴结转移的患者，可能从辅助化疗受益。姑息化疗在改善晚期患者无进展生存期和总生存期中可能发挥作用。晚期患者使用FOLFOX方案（氟尿嘧啶、亚叶酸钙和奥沙利铂）疗效优于其他方案。对于小肠癌分子靶向治疗尚处在探索中，而化疗亦有待进一步深入研究。

关键词: 肠肿瘤, 药物疗法, 分子靶向治疗

Abstract: Neoplasms of the small intestine have no specific features at early stage，and the prognosis is poor. The 5year survival rate of all the patients is about 30% and the middle survival time is 19 months. The retrospective analysis shows that adjuvant chemotherapy after surgical resection might improve the disease free survival while the overall survival is not improved obviously. The patients who are at advanced stage or have regional lymph node metastasis may obtain benefits from adjuvant chemotherapy. Palliative chemotherapy may improve progress free survival and overall survival  of patients who are at advanced stage. The therapeutic effect of patients at advanced stage using FOLFOX regimen（5fluorouracil，calcium folinate and oxaliplatin）is better compared with other regimens. The molecular targeted therapy of small intestine cancer is still in the study process and advanced studies are also needed for chemotherapy.

Key words: Intestinal neoplasms, Drug therapy, Molecular targeted therapy